exemestane + palbociclib

## Drug Information Exemestane + palbociclib is a combination therapy used primarily in hormone receptor-positive (HR+), HER2-negative breast cancer. This combination pairs an aromatase inhibitor (exemestane) with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (palbociclib) to provide a targeted approach for treating breast cancer. ## Mechanism of Action The combination works through complementary mechanisms: - **Exemestane** functions as an aromatase inhibitor, reducing estrogen production which is crucial for hormone receptor-positive breast cancer growth[3]. - **Palbociclib** is an oral CDK4/6 inhibitor that blocks cell cycle progression, preventing cancer cell proliferation. It appears to be synergistic with endocrine therapy in both preclinical and clinical studies[1]. ## Clinical Applications This combination is primarily used in: - Postmenopausal patients with HR+/HER2- metastatic breast cancer (MBC) who have developed resistance to non-steroidal aromatase inhibitors (NSAI) like letrozole or anastrozole[1][3]. - Premenopausal HR+/HER2- metastatic breast cancer patients when combined with ovarian function suppression (OFS)[2]. ## Clinical Evidence The PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006) was a Phase III international trial comparing exemestane + palbociclib versus capecitabine in patients with HR+/HER2- metastatic breast cancer who had developed resistance to previous non-steroidal aromatase inhibitors[1]. The Young-PEARL study specifically evaluated this combination in premenopausal patients, showing: - Improved progression-free survival (PFS) compared to capecitabine (19.5 months vs. 14.0 months) - No significant overall survival benefit (54.8 months vs. 57.8 months) - A manageable safety profile with longer follow-up[2]. ## Dosing The typical dosing regimen includes: - Exemestane: 25 mg daily - Palbociclib: 125 mg daily for 3 weeks followed by 1 week off (in a 4-week cycle)[1][3]. ## Safety Profile Common adverse effects include: - For exemestane: osteoporosis, headache, hot flushes, arthralgia, fatigue, and liver abnormalities - For palbociclib: myelosuppression (particularly neutropenia), infections, fatigue, and mucositis[3]. The combination has shown a manageable safety profile in clinical trials, though grade ≥3 adverse events are more common with the combination therapy compared to capecitabine alone (93.5% vs. 48.2%)[2].